A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric ...
Dec 9, 2019
0
5
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) today announced results from an extended follow-up analysis of patients in its randomized Phase 3 clinical trial, E1912. The results show that the combination of ibrutinib, ...
Dec 7, 2019
0
4
Metformin is the most commonly prescribed type 2 diabetes drug, yet scientists still do not fully know how it works to control blood sugar levels. In a collaborative effort, researchers from the Salk Institute, The Scripps ...
Dec 3, 2019
0
1710
A new screening system developed by scientists at the UCLA Jonsson Comprehensive Cancer Center leverages redundancy in an important component of a cell—nucleotide metabolism—to help identify new drugs that specifically ...
Nov 18, 2019
2
3
A team of researchers affiliated with a large number of institutions in the U.S. has found that a subgroup of breast cancers have two PIK3CA mutations, and that such mutations occur on the same allele. In their paper published ...
Why do some cancers come back? Sometimes, a treatment can effectively eliminate cancer cells to undetectable levels, but, if the treatment stops, cancer may return. This is the case of chronic myeloid leukemia treated with ...
Nov 7, 2019
0
34
An unexplored kinase in heart muscle cells may be a good target to treat heart failure, a disease that is only incrementally delayed by existing therapies. Failing human hearts showed reduced amounts of this kinase, and preclinical ...
Oct 31, 2019
0
0
Neuroscientists at Georgetown University Medical Center say they have developed and tested an agent that reduces the buildup of toxic proteins in animal models of both Parkinson's and Alzheimer's diseases, and improves cognitive ...
Oct 23, 2019
0
473
The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80 percent of people with CML who received the drug, the disease went into complete ...
Oct 16, 2019
0
1021
No matter the pathogen—virus, bacterium or fungus—many "pick a specific type of lock" on the surface of cells, which allows the microbe to break and enter into the inner sanctum of the host's genome.
